fondaparinux / Generic mfg. - LARVOL DELTA

Extensive Portomesenteric Venous Thrombosis Associated With Testosterone-Induced Erythrocytosis (ACG 2026) - "The patient was discharged on fondaparinux (warfarin contraindicated due to antiretroviral interactions) with symptomatic improvement and later transitioned to apixaban. Superior mesenteric venography (A) before and (B) after catheter-directed intervention Legend: (A) Complete occlusion of the superior mesenteric vein with absence of flow (red arrow). (B) Restored hepatopedal flow through the superior mesenteric vein following intervention."

Cardiovascular • Endocrine Disorders • Hematological Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammatory Arthritis • Thrombosis

Fondaparinux versus regional citrate anticoagulation in artificial liver support for patients with liver failure and high bleeding risk: A pilot randomized controlled trial. (PubMed, Transfus Apher Sci) - "Fondaparinux showed no statistically significant difference from RCA in the composite endpoint and reduced monitoring burden and procedural cost. These pilot findings support a larger multicenter trial; definitive non-inferiority was not established."

Journal • Cardiovascular • Hematological Disorders • Hepatology • Liver Failure • Thrombosis

Anticoagulants, Their Laboratory Monitoring, and Reversal. (PubMed, Hematol Rep) - "This review provides an overview of the major classes of anticoagulants, including unfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux, direct thrombin inhibitors, VKAs, and DOACs, with emphasis on their mechanisms of action, clinical applications, laboratory monitoring, and reversal strategies...The development of targeted reversal agents, including protamine, vitamin K, prothrombin complex concentrates, idarucizumab, and andexanet alfa, has significantly enhanced the safety of anticoagulant therapy in the setting of major bleeding or urgent procedures...Emerging anticoagulants targeting factors XI, XII, and XIII represent a promising future direction with the potential to further reduce bleeding risk while maintaining efficacy. Overall, continued advances in anticoagulant pharmacology, monitoring, and reversal strategies are driving a shift toward safer and more individualized patient care."

Journal • Review • Cardiovascular • Hematological Disorders • Thrombocytopenia

ANTICOAGULATION IN HEPARIN-INDUCED THROMBOCYTOPENIA: FATAL INTRACRANIAL HEMORRHAGE DURING FONDAPARINUX THERAPY (CHEST 2026) - No abstract available

Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Thrombocytopenia

Sulfated polysaccharides and their utilization mechanisms by microorganisms: A review. (PubMed, Int J Biol Macromol) - "It explored the structural composition of four typical SPS namely heparin, chondroitin sulfate, fucoidan, and fondaparinux sodium, as well as their biological activities, including antiviral, antioxidant, antitumor, anticoagulant, and immunomodulatory effects...The roles of various active enzymes in the degradation process were analyzed, and the role of SPS synthesized by microorganisms themselves in their survival and development was discussed. The unique structure of SPS and their corresponding biological activities gave them enormous application potential in fields such as synthetic biology, metabolic engineering, and healthcare."

Journal • Review • Developmental Disorders • Oncology

The anticoagulation dilemma: A case report of pulmonary embolism in a gastric cancer patient with concurrent gastrointestinal bleeding and thrombocytopenia. (PubMed, Medicine (Baltimore)) - "This case underscores the importance of individualized anticoagulation strategies in patients with cancer and PE, particularly those at high risk of bleeding or heparin-induced thrombocytopenia. This highlights the need for further research and clinical guidelines to optimize the management of venous thromboembolism in this vulnerable population. However, owing to the lack of relevant laboratory testing resources at our medical institution, we were unable to confirm this through laboratory verification."

Journal • Cardiovascular • Gastric Cancer • Gastroenterology • Hematological Disorders • Oncology • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • Thrombocytopenia • Venous Thromboembolism

Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. (PubMed, JAMA) - P=N/A | "Physicians and patients selected any DOAC or any LMWH (or fondaparinux) and physicians selected drug doses...These findings support use of a DOAC to prevent recurrent VTE in patients with cancer. ClinicalTrials.gov Identifier: NCT02744092."

Clinical • Journal • Cardiovascular • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Oncology • Solid Tumor • Venous Thromboembolism

Synthetic Heparan Sulfate-like Oligosaccharides as Tools to Decipher Growth Factor Recognition. (PubMed, J Med Chem) - "Compound 8, synthesized in two steps, competitively disrupted heparin binding to FGF2 (IC50 = 0.23 μM), FGFR1 (IC50 = 0.17 μM), and VEGF165 (IC50 = 0.66 μM), with >140-fold FGF2/FGF4 selectivity and substantially greater potency than native HS pentasaccharide fondaparinux. In NIH3T3 fibroblasts, compound 8 selectively reduced FGF2-induced proliferation in a dose-dependent manner without measurable cytotoxicity, highlighting aminoglycoside-derived HS mimetics as synthetically accessible platforms for modulating growth factor signaling."

Journal • FGF2 • FGF4 • FGFR1

Characterization of glycosaminoglycan interactions with the chemokine CCL20 (MIP3α) and its carboxyterminal antimicrobial and antibiofilm peptide. (PubMed, Biochim Biophys Acta Biomembr) - "The binding and oligomerization of chemokines to cell surface glycosaminoglycans (GAG) can play an important role during receptor activation; therefore we have studied the interactions of CCL20 with fondaparinux...It also displayed somewhat lower activities against the Gram-negative Pseudomonas aeruginosa PAO1 strain. These results highlight the potential of CCL20-(51-70) as a potent host-defence peptide, that could play a role in eradicating bacterial biofilms, particularly for Gram-positive pathogenic bacteria."

Journal • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Septic Shock • CCL20

Eleven years of balloon pulmonary angioplasty in a single center: insights into safety and efficacy (ESC 2026) - "All patients received lifelong anticoagulation therapy (vitamin K antagonists: 34 patients; direct oral anticoagulants: 44; fondaparinux: 1)...One death occurred as sudden death during hospitalization. Conclusions BPA is safe and effective at improving symptoms and hemodynamic profile in inoperable CTEPH patients and in patients with residual PH after PEA."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Embolism

Low molecular weight heparin for AMI with frailty: short-Term outcomes after early PCI (ESC 2026) - "Patients were stratified into the LMWH group and control group (no LMWH, fondaparinux, or bivalirudin). In frail patients with AMI undergoing early PCI, the use of low molecular weight heparin demonstrates benefits in short-term cardiovascular, cerebrovascular and net adverse clinical events."

Cardiovascular • Coronary Artery Disease • Ischemic stroke • Myocardial Infarction

Prognostic impact of post-procedural low-molecular-weight heparin in high-bleeding risk patients undergoing pci for acute myocardial infarction (ESC 2026) - "Key exclusion criteria included malignancy, specific high-risk arrhythmias (ventricular tachycardia/fibrillation, sinus arrest), Killip class III-IV, use of alternative anticoagulants (bivalirudin, fondaparinux), or oral anticoagulants.The primary endpoint was 30-day all-cause mortality. In this real-world cohort of AMI patients with HBR undergoing PCI, the use of post-procedural LMWH was associated with a significantly lower risk of 30-day all-cause mortality without a significant increase in major bleeding events. These findings suggest a favorable net clinical benefit for LMWH in this high-risk population, warranting further validation in prospective randomized trials."

Clinical • Cardiovascular • Myocardial Infarction • Ventricular Tachycardia

Clinical pharmacist-guided management of heparin-induced thrombocytopenia with thrombosis after hip hemiarthroplasty: a case report. (PubMed, Front Cardiovasc Med) - "Enoxaparin was discontinued, and anticoagulation was switched to fondaparinux sodium. This case highlights the importance of timely assessment of HIT probability and multidisciplinary collaboration. Clinical pharmacists may contribute to the early diagnosis, appropriate anticoagulant modification, and individualized management of patients with complex anticoagulation needs."

Journal • Cardiovascular • Hematological Disorders • Orthopedics • Pulmonary Embolism • Thrombocytopenia • Thrombosis

An Italian cartography of VEXAS-related thrombosis. (PubMed, Hemasphere) - "Treatments comprised direct oral anticoagulants (DOACs) (51%), low molecular weight heparin (LMWH) (28%), Fondaparinux (14%), and vitamin K antagonists (AVKs) (7%). Notably, 27% experienced multiple TEs, of which 22% occurring despite anticoagulation during disease flares. Our findings provide an updated cartography of VEXAS-related TE, suggesting early screening for thrombophilia in these patients to inform both personalized anticoagulation and disease-control strategies."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

2-Naphthylmethyl Protecting Group Strategy for Streamlined Synthesis of a Fondaparinux Analogue. (PubMed, Org Lett) - "Direct C-2 Nap installation, combined with C-6 2-(diphenylphosphinoyl)acetyl (DPPA)-assisted β-glucosylation, streamlined assembly, while Nap-mediated phase behavior enabled 17 of 20 intermediates to be isolated without chromatography. The final analogue showed anti-FXa activity comparable to commercial fondaparinux."

Journal

Safety and efficacy of fondaparinux in pediatric venous thromboembolism: A retrospective cohort study. (PubMed, Thromb Res) - "This largest pediatric fondaparinux cohort demonstrates rapid therapeutic anticoagulation, clinically meaningful clot resolution, and low bleeding risk using standardized dosing and ISTH-harmonized endpoints, supporting its role as a once-daily parenteral option when DOACs are unsuitable and informing pediatric labeling."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Pediatrics • Venous Thromboembolism

Drugs to Prevent and Treat Venous Thromboembolic Disease During Pregnancy. (PubMed, Clin Perinatol) - "Here, we summarize the features of anticoagulants used in pregnancy. Despite the advent of newer agents, the most common anticoagulant used in pregnancy remains heparin derivatives (primarily the low-molecular-weight forms)."

Journal • Review • Cardiovascular • Obstetrics • Venous Thromboembolism

Mesoglycan for long-term secondary prevention in patients with superficial vein thrombosis (METRO): a multicentre randomised clinical trial in Italy. (PubMed, EClinicalMedicine) - P2 | "Patients (aged > 18 years) with lower-limb SVT, who completed a 45-day treatment course of fondaparinux were randomised (1:1) to receive either oral MGY 50 mg or matching placebo twice-daily for 12 months, and were subsequently followed-up for another 12 months...Our findings need to be confirmed in future, larger studies. Neopharmed Gentili S.p.A."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Who says "no" - Patient-specific risk factors for refusal of venous thromboembolism chemoprophylaxis in hospitalized patients. (PubMed, Thromb Res) - "This study identified several patient-specific characteristics associated with increased and decreased risk of VTE chemoprophylaxis refusal. Additionally, variance in rates of refusal was noted across hospital units. Identification of factors associated with VTE chemoprophylaxis refusal may help inform targeted interdisciplinary education and intervention strategies."

Journal • Cardiovascular • Psychiatry • Venous Thromboembolism

Pharmacological thromboprophylaxis in hospitalized patients with acute infectious diseases: a meta-analysis. (PubMed, Eur J Clin Pharmacol) - "This analysis quantifies the effect of thromboprophylaxis in patients with acute infectious diseases. Although available results show that thromboprophylaxis is associated with fewer VTE events, limited data, sparse safety and mortality reporting, and heterogeneity among studies preclude reliable risk-benefit evaluation. Further prospective research is warranted."

Clinical • Journal • Retrospective data • Review • Cardiovascular • CNS Disorders • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Pulmonary Embolism • Respiratory Diseases • Septic Shock • Venous Thromboembolism

Room-Temperature Stability of Argatroban, Danaparoid, and Fondaparinux in Plasma: A Multicenter Study. (PubMed, Thromb Haemost) - "no need."

Clinical • Journal

Precision Medicine for Anticoagulation Strategies in the Cath Lab: Part 1. (PubMed, Curr Cardiol Rep) - "Fondaparinux has been associated with an increased risk of catheter-related thrombosis and therefore should not be used as a stand-alone intraprocedural anticoagulant during PCI. In PCI, contemporary randomized trials and guideline recommendations support UFH as standard therapy, with enoxaparin and bivalirudin as effective alternatives depending on clinical presentation and bleeding risk. Further studies are needed to refine anticoagulation strategies based on individualized risk factors and procedural context in contemporary PCI."

Journal • Review • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Hematological Disorders • Myocardial Infarction • Thrombocytopenia • Thrombosis

A Universal Coagulation Assay for Detecting, Identifying, and Quantifying Currently Available Non–VKA Anticoagulants: An Artificial Intelligence Approach (ISTH 2026) - "Three feature s Results Our results demonstrate sensitivity across the following concentration ranges: heparin sodium, 0.0–2.0 IU/mL; enoxaparin sodium, 0.0–2.0 IU anti-Xa/mL; fondaparinux sodium, 0.0–2.0 µg/mL; rivaroxaban, apixaban, edoxaban, and dabigatran, 0.0–4 Conclusions This study demonstrates the feasibility of an AI-based universal assay for detecting, identifying, and quantifying currently available non–VKA anticoagulants. DOI*"

Thrombosis

Tailoring therapy for acute myocardial infarction and de novo severe immune thrombocytopenia – a case report (ISTH 2026) - "Results The patient received peroral acetylsalicylic acid (300 mg ) and ticagleror (180 mg) and was immediately referred to percutaneous coronary intervention (PCI). During procedure parenteral unfractionated heparin was administered (10000 IU) alongside dilatation manoeuvre in the right coronary artery occlusion with intracardiac eptifibatide delivery (50 mg) due to the vast thrombus...On the 2 nd day of hospitalization peroral antiaggregation therapy was continued and clopidogrel was introduced (75 mg per day) to prevent coronary rethrombosis...Later on, therapeutic doses of fondaparinux were introduced due to atrial fibrillation paroxysms...However, a clear consensus on the treatment in these specific circumstances is needed. Table or Figure Upload (1) Laboratory parameters during the patient's hospitalization Page 2 DOI*10.1016/j.rpth.2026.106584"

Case report • Clinical • Acute Coronary Syndrome • Atrial Fibrillation • Cardiovascular • Genetic Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Myocardial Infarction • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis

Direct Oral Anticoagulants Versus Direct Thrombin Inhibitors for Heparin-Induced Thrombocytopenia: A Propensity Score-Matched Analysis Using MIMIC-IV (ISTH 2026) - "Results Among 589 patients (DOAC: 278; DTI: 241; fondaparinux: 70), propensity matching yielded 128 well- balanced pairs (Figure 1)...Kaplan-Meier Survival Curves for Mortality in the Propensity-Matched Cohort. DOI*10.1016/j.rpth.2026.106074"

Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis